BioSpace News Archive

Shifamed LLC announced that Apama Medical was acquired by Boston Scientific Corporation for $175M in cash up-front and a maximum of $125M in contingent payments over the period of 2018-2020, based on achievements of clinical and regulatory milestones.

Aethlon Medical announced today that it has established a collaboration with iBio to support potential large-scale production of the Aethlon Hemopurifier.

Aries Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of May 21st, 2018, for its decision on the New Drug Application (NDA) for Methylene Blue MMX (MB MMX).

HyperMed Imaging, Inc. announced today that the company is now offering for sale its new HyperView Imaging System to customers in the United States.

Ipsen and its partner Exelixis today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS)

Agile Therapeutics today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch, Twirla.

Dicerna Pharmaceuticals, Inc., today announced the first submission of a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1 clinical trial of DCR-PHXC, the company’s most advanced GalXCTM product candidate, for the potential treatment of primary hyperoxaluria (PH).

The Parker Institute for Cancer Immunotherapy today announced that researchers at Dana-Farber Cancer Institute have joined its network.

Nephros is providing a general update on the Company’s activities and guidance for the third quarter of 2017.

Creative Medical Technology Holdings announced today filing of a patent application using a combination of an FDA approved drug together with the patient’s own bone marrow derived stem cells for the treatment of stroke.